Brian Drapeau

The future of compliant AI is not better content generation. It is better control over what happens next.

In this episode of Drug Digest, experts from Sanofi, GxP Frame, and Open Biopharma explain how AI is transforming drug discovery, manufacturing, and workforce strategy and how strategic partnerships play a role.

A warning letter, a hard look at why “a human reviews it” doesn’t settle anything, and one company’s argument that accuracy was never the real problem.

The cell and gene therapy manufacturing workforce is having to expand on deliverables while remaining under trained.